|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Surveillance, Epidemiology, and End
Results (SEER): Program Research Data (1973–2007). National Cancer
Institute, DCCPS, Surveillance Research Program, Surveillance
Systems Branch. 2010.
|
|
3
|
Sener SF, Fremgen A, Menck HR and
Winchester DP: Pancreatic cancer: A report of treatment and
survival trends for 100,313 patients diagnosed from 1985–1995,
using the national cancer database. J Am Coll Surg. 189:1–7. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardiére C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Greenhalf W, Ghaneh P, Neoptolemos JP,
Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR,
Costello E, et al: Pancreatic cancer hENT1 expression and survival
from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer
Inst. 106:djt3472014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakagawa N, Murakami Y, Uemura K, Sudo T,
Hashimoto Y, Kondo N and Sueda T: Combined analysis of intratumoral
human equilibrative nucleoside transporter 1 (hENT1) and
ribonucleotide reductase regulatory subunit M1 (RRM1) expression is
a powerful predictor of survival in patients with pancreatic
carcinoma treated with adjuvant gemcitabine-based chemotherapy
after operative resection. Surgery. 153:565–575. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ashida R, Nakata B, Shigekawa M, Mizuno N,
Sawaki A, Hirakawa K, Arakawa T and Yamao K: Gemcitabine
sensitivity-related mRNA expression in endoscopic ultrasound-guided
fine-needle aspiration biopsy of unresectable pancreatic cancer. J
Exp Clin Cancer Res. 28:832009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farrow B, Sugiyama Y, Chen A, Uffort E,
Nealon W and Mark Evers B: Inflammatory mechanisms contributing to
pancreatic cancer development. Ann Surg. 239:763–771. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lesina M, Kurkowski MU, Ludes K, Rose-John
S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S,
et al: Stat3/Socs3 activation by IL-6 trans-signaling promotes
progression of pancreatic intraepithelial neoplasia and development
of pancreatic cancer. Cancer Cell. 19:456–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Logsdon CD, Simeone DM, Binkley C,
Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R and Hanash
S: Molecular profiling of pancreatic adenocarcinoma and chronic
pancreatitis identifies multiple genes differentially regulated in
pancreatic cancer. Cancer Res. 63:2649–2657. 2003.PubMed/NCBI
|
|
12
|
Yamanaka T, Matsumoto S, Teramukai S,
Ishiwata R, Nagai Y and Fukushima M: The baseline ratio of
neutrophils to lymphocytes is associated with patient prognosis in
advanced gastric cancer. Oncology. 73:215–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chua W, Charles KA, Baracos VE and Clarke
SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in
patients with advanced colorectal cancer. Br J Cancer.
104:1288–1295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim
KH and Kim HJ: Prognostic significance of neutrophil lymphocyte
ratio and platelet lymphocyte ratio in advanced gastric cancer
patients treated with FOLFOX chemotherapy. BMC Cancer. 13:3502013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Absenger G, Szkandera J, Pichler M, Stotz
M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H,
Stojakovic T and Gerger A: A derived neutrophil to lymphocyte ratio
predicts clinical outcome in stage II and III colon cancer
patients. Br J Cancer. 109:395–400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Absenger G, Szkandera J, Stotz M,
Postlmayr U, Pichler M, Ress AL, Schaberl-Moser R, Loibner H,
Samonigg H and Gerger A: Preoperative neutrophil-to-lymphocyte
ratio predicts clinical outcome in patients with stage II and III
colon cancer. Anticancer Res. 33:4591–4594. 2013.PubMed/NCBI
|
|
17
|
Martin HL, Ohara K, Kiberu A, Van Hagen T,
Davidson A and Khattak MA: Prognostic value of systemic
inflammation-based markers in advanced pancreatic cancer. Intern
Med J. 44:676–682. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szkandera J, Stotz M, Eisner F, Absenger
G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R,
Alzoughbi W, Ress AL, et al: External validation of the derived
neutrophil to lymphocyte ratio as a prognostic marker on a large
cohort of pancreatic cancer patients. PLoS One. 8:e782252013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Proctor MJ, McMillan DC, Morrison DS,
Fletcher CD, Horgan PG and Clarke SJ: A derived neutrophil to
lymphocyte ratio predicts survival in patients with cancer. Br J
Cancer. 107:695–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakano Y, Tanno S, Koizumi K, Nishikawa T,
Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo
Y: Gemcitabine chemoresistance and molecular markers associated
with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br J Cancer. 96:457–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Farrell JJ, Elsaleh H, Garcia M, Lai R,
Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, et
al: Human equilibrative nucleoside transporter 1 levels predict
response to gemcitabine in patients with pancreatic cancer.
Gastroenterology. 136:187–195. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haas M, Heinemann V, Kullmann F, Laubender
RP, Klose C, Bruns CJ, Holdenrieder S, Modest DP, Schulz C and
Boeck S: Prognostic value of CA 19–9, CEA, CRP, LDH, and bilirubin
levels in locally advanced and metastatic pancreatic cancer:
Results from a multicenter, pooled analysis of patients receiving
palliative chemotherapy. J Cancer Res Clin Oncol. 139:681–689.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mitsunaga S, Ikeda M, Shimizu S, Ohno I,
Furuse J, Inagaki M, Higashi S, Kato H, Terao K and Ochiai A: Serum
levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in
patients with advanced pancreatic cancer. Br J Cancer.
108:2063–2069. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eto K, Kawakami H, Kuwatani M, Kudo T, Abe
Y, Kawahata S, Takasawa A, Fukuoka M, Matsuno Y, Asaka M and
Sakamoto N: Human equilibrative nucleoside transporter 1 and Notch3
can predict gemcitabine effects in patients with unresectable
pancreatic cancer. Br J Cancer. 108:1488–1494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goldstein D, El-Maraghi RH, Hammel P,
Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S,
Tabernero J, Teixeira L, et al: Nab-paclitaxel plus gemcitabine for
metastatic pancreatic cancer: Long-term survival from a phase III
trial. J Natl Cancer Inst. 107:doi: 10.1093/jnci/dju413. 2015.
View Article : Google Scholar
|
